⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 3 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Susmita Ghosh Fan Fan Reid T. Powell Jason Roszik Yong Sung Park Clifford Stephan Manu Sebastian Lin Tan Alexey V. Sorokin Philip L. Lorenzi Scott Kopetz Lee M. Ellis Rajat Bhattacharya

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 3 shows that the combination of trametinib and vincristine inhibits tumor growth and reduces tumor weight in PDX C1138

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ghosh et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875237a8 https://doi.org/10.1158/1535-7163.27036217

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 3 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
2Supplementary Figure 2 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
3Supplementary Figure 2 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
4Supplementary Figure 1 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
5Supplementary Figure 1 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024

More related papers

Supplementary Figure 4 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
Supplementary Figure 4 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
Supplementary Figure 6 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024